Argyro Syngelaki1, Reena Kotecha1, Alice Pastides1, Alan Wright2, Kypros H Nicolaides3. 1. Harris Birthright Research Centre of Fetal Medicine, King's College Hospital, London, UK. 2. Institute of Health Research, University of Exeter, Exeter, UK. 3. Harris Birthright Research Centre of Fetal Medicine, King's College Hospital, London, UK. Electronic address: kypros@fetalmedicine.com.
Abstract
OBJECTIVE: To investigate whether first-trimester biochemical markers of placentation, including pregnancy-associated plasma protein-A (PAPP-A) and placental growth factor (PLGF), are altered in women that subsequently develop gestational diabetes mellitus (GDM) and to examine their potential value in improving the performance of screening for GDM by maternal characteristics and medical history. METHODS: The study population of 31,225 singleton pregnancies, including 787 cases that developed GDM, was drawn from women undergoing routine prospective screening for pregnancy complications at 11-13 weeks' gestation. Maternal serum PAPP-A and PLGF were measured and the levels were expressed as multiples of the median (MoM) after adjustment for maternal characteristics and medical history. The performance of screening for GDM by maternal factors and MoM values of PAPP-A and PLGF was evaluated by receiver operating characteristic (ROC) curves. RESULTS: In the GDM group, compared to the unaffected group, the median PAPP-A was reduced (0.949, 95% CI 0.913-0.987 MoM) (p=0.0009) and median PLGF was increased (1.053, 95% CI 1.023-1.083 MoM) (p=0.004). The performance of screening for GDM by maternal factors was not improved by the addition of PAPP-A and/or PLGF. CONCLUSIONS: First trimester maternal serum PAPP-A and PLGF are not useful in screening for GDM.
OBJECTIVE: To investigate whether first-trimester biochemical markers of placentation, including pregnancy-associated plasma protein-A (PAPP-A) and placental growth factor (PLGF), are altered in women that subsequently develop gestational diabetes mellitus (GDM) and to examine their potential value in improving the performance of screening for GDM by maternal characteristics and medical history. METHODS: The study population of 31,225 singleton pregnancies, including 787 cases that developed GDM, was drawn from women undergoing routine prospective screening for pregnancy complications at 11-13 weeks' gestation. Maternal serum PAPP-A and PLGF were measured and the levels were expressed as multiples of the median (MoM) after adjustment for maternal characteristics and medical history. The performance of screening for GDM by maternal factors and MoM values of PAPP-A and PLGF was evaluated by receiver operating characteristic (ROC) curves. RESULTS: In the GDM group, compared to the unaffected group, the median PAPP-A was reduced (0.949, 95% CI 0.913-0.987 MoM) (p=0.0009) and median PLGF was increased (1.053, 95% CI 1.023-1.083 MoM) (p=0.004). The performance of screening for GDM by maternal factors was not improved by the addition of PAPP-A and/or PLGF. CONCLUSIONS: First trimester maternal serum PAPP-A and PLGF are not useful in screening for GDM.
Authors: Brittney M Snyder; Rebecca J Baer; Scott P Oltman; Jennifer G Robinson; Patrick J Breheny; Audrey F Saftlas; Wei Bao; Andrea L Greiner; Knute D Carter; Larry Rand; Laura L Jelliffe-Pawlowski; Kelli K Ryckman Journal: Diabetes Res Clin Pract Date: 2020-04-06 Impact factor: 5.602
Authors: Julia Alanen; Heidi Appelblom; Teemu Korpimaki; Heikki Kouru; Mikko Sairanen; Mika Gissler; Markku Ryynanen; Jaana Nevalainen Journal: Arch Gynecol Obstet Date: 2020-07-11 Impact factor: 2.344
Authors: Clive J Petry; Ken K Ong; Ieuan A Hughes; Carlo L Acerini; Jan Frystyk; David B Dunger Journal: J Clin Endocrinol Metab Date: 2017-06-01 Impact factor: 5.958
Authors: Brittney M Donovan; Nichole L Nidey; Elizabeth A Jasper; Jennifer G Robinson; Wei Bao; Audrey F Saftlas; Kelli K Ryckman Journal: PLoS One Date: 2018-07-26 Impact factor: 3.240